Entering text into the input field will update the search result below

Amylyx Pharmaceuticals: Targeting Multiple Destructive Pathways To Reduce Neuronal Death

Jan. 03, 2022 2:42 PM ETAmylyx Pharmaceuticals, Inc. (AMLX)


  • Amylyx Pharmaceuticals is developing combo therapies to reduce neuronal death in ALS and other neurodegenerative diseases by targeting multiple destructive pathways.
  • The Company’s NDA for its lead candidate AMX0035 has been accepted by the FDA for priority review with PDUFA date in June 2022.
  • The Company has filed a form S-1 registration statement for a $100 million IPO.
  • Looking for more investing ideas like this one? Get them exclusively at The Total Pharma Tracker. Learn More »

Brown University

peterspiro/iStock via Getty Images


Amylyx logo

Setting out from a dorm room at Brown University in 2013, Joshua Kohen and Justin Klee began research on neuronal death as co-founders and co-CEOs of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX), working on developing

About the TPT service

Thanks for reading. At the Total Pharma Tracker, we offer the following:-

Our Android app and website features a set of tools for DIY investors, including a work-in-progress software where you can enter any ticker and get extensive curated research material. 

For investors requiring hands-on support, our in-house experts go through our tools and find the best investible stocks, complete with buy/sell strategies and alerts.

Sign up now for our free trial, request access to our tools, and find out, at no cost to you, what we can do for you. 

This article was written by

Avisol Capital Partners profile picture

Avisol Capital Partners is made up of a team of medical experts, finance professionals and techies, all of whom invest their own money in the picks they share. They aim to help readers find the middle ground between value and growth investing, as they demystify the biopharma industry.

They lead the investing group Total Pharma Tracker where they offer a monthly updated catalyst database, an investability scoring system for quick reference ideas, and direct access in chat for dialogue and questions. Learn more.

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You


Disagree with this article? Submit your own. To report a factual error in this article, . Your feedback matters to us!
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.